Precision medicine and personalized breast cancer: combination pertuzumab therapy. - Test2 - elhamkhani - TriplyDB

Precision medicine and personalized breast cancer: combination pertuzumab therapy.

Precision medicine and personalized breast cancer: combination pertuzumab therapy.

http://www.wikidata.org/entity/Q37687975

about

Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer.

P2860

Q50975813-0A1F016C-3172-446F-BD6C-81175EF34582

P2860

Precision medicine and personalized breast cancer: combination pertuzumab therapy.

http://www.wikidata.org/entity/Q37687975

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 March 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Precision medicine and personalized breast cancer: combination pertuzumab therapy.

@en

Precision medicine and personalized breast cancer: combination pertuzumab therapy.

@nl

type

label

Precision medicine and personalized breast cancer: combination pertuzumab therapy.

@en

Precision medicine and personalized breast cancer: combination pertuzumab therapy.

@nl

prefLabel

Precision medicine and personalized breast cancer: combination pertuzumab therapy.

@en

Precision medicine and personalized breast cancer: combination pertuzumab therapy.

@nl

P1433

Q37687975-6D8AC9CB-3CE5-47A2-9A28-61A30732024D

P1476

Q37687975-E0C43FC5-37C7-4BE0-8396-CBACD72E9F62

P2093

Q37687975-3449210D-C652-4F98-8F92-ACEF07277FFF

Q37687975-3BF85CF0-30D9-4845-B5A5-5CE46BC0BBE9

Q37687975-5A04E0B8-D0B3-43BA-BD5A-C5D98F34DB0E

Q37687975-C70630A2-F59A-4AFE-BCD3-596F9F16F1C0

P2860

Q37687975-0DB536F2-4244-49ED-82C8-6B900ABCF862

Q37687975-0EF6B6C8-6D22-4228-907C-2D49E5085ABD

Q37687975-139DB15D-4E69-4D14-A955-F5709661FA45

Q37687975-16688DD1-7A99-4E64-A3CA-49FF934D1545

Q37687975-16CEC147-DBF1-4F08-8081-AA43FE7C478B

Q37687975-31E7E779-0FE7-427D-B717-319F38923671

Q37687975-32CA4719-3616-47B0-9158-953A751B4A71

Q37687975-32E6FD50-6A60-4D11-913F-C39408CE307C

Q37687975-35D697E3-2029-4719-A2D1-D2EBA3039A01

Q37687975-3D37FF45-B61E-4CA7-9E3C-5C0A8896DC81

P304

Q37687975-98051A3D-6E3D-48FF-8D15-A25E21D7A28C

P31

Q37687975-2E76F713-C8AE-476F-B216-DC351D8FB7D7

P356

Q37687975-3A32E7C4-30E9-459D-8C87-E2AAC590297F

P478

Q37687975-91B98AC6-CA38-4EFA-A679-67D1AE0FCEB7

P577

Q37687975-813A1173-5BFF-4C9B-B0E6-A1F69B069C05

P698

Q37687975-F22502A2-3DAC-473B-AF52-BCCAC290634F

P921

Q37687975-f0438e62-4858-6f6e-e248-0f2f5124d256

P932

Q37687975-7D3B3894-179B-4A2A-BDBB-D6FB1FC37EF3

P356

P1433

Pharmacogenomics and Personalized Medicine

P1476

Precision medicine and personalized breast cancer: combination pertuzumab therapy.

@en

P2093

Aditya Bardia

http://www.w3.org/2001/XMLSchema#string

Don S Dizon

http://www.w3.org/2001/XMLSchema#string

Kerry Reynolds

http://www.w3.org/2001/XMLSchema#string

Sasmit Sarangi

http://www.w3.org/2001/XMLSchema#string

P2860

Neoadjuvant therapy as a platform for drug development and approval in breast cancer

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me

P304

95-105

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/PGPM.S37100

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24715764

http://www.w3.org/2001/XMLSchema#string

P921

P932

3977457

http://www.w3.org/2001/XMLSchema#string